A new Phase I clinical trial from London Health Sciences Centre Research Institute (LHSCRI) has found high-precision radiation therapy is safe for use in patients with cancer that has spread to more than 10 spots in the body. Published in the International Journal of Radiation Oncology, Biology, Physics, the ARREST trial highlights the potential of this therapy for patients with limited treatment options.

Past research from LHSCRI has shown that targeted radiation, called stereotactic ablative radiotherapy (SABR), may be beneficial for those with cancers that have spread or metastasized to fewer than 10 spots by showing it can lengthen the time until new cancer spots appear and, in some patients, lengthen their lifespan. This study aimed to assess the safety and feasibility of using stereotactic ablative


radiotherapy in cancer patients with polymetastatic disease – where the cancer has spread to more than 10 spots in multiple organs throughout the body – who have very few drug treatment options available to them.

Curtesy: Dr. Bhumika Maikhuri
View More